25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Risk Score for Predicting 2‐Year Mortality in Patients With Chagas Cardiomyopathy From Endemic Areas: SaMi‐Trop Cohort Study

      research-article
      , MD, PhD 1 , , MD, PhD 2 , , PhD 3 , , MS 3 , , MD, PhD 1 , , PhD 4 , , MD, PhD 5 , , MD 5 , , MD, PhD 6 , , MD, PhD 4 , , PhD 7 , , MD, PhD 7 , , MD, PhD 8 , , MD, PhD 2 ,
      Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
      John Wiley and Sons Inc.
      Chagas cardiomyopathy, Chagas disease, mortality, risk prediction, risk score, Cardiomyopathy, Inflammatory Heart Disease

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Risk stratification of Chagas disease patients in the limited‐resource setting would be helpful in crafting management strategies. We developed a score to predict 2‐year mortality in patients with Chagas cardiomyopathy from remote endemic areas.

          Methods and Results

          This study enrolled 1551 patients with Chagas cardiomyopathy from Minas Gerais State, Brazil, from the SaMi‐Trop cohort (The São Paulo‐Minas Gerais Tropical Medicine Research Center). Clinical evaluation, ECG, and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) were performed. A Cox proportional hazards model was used to develop a prediction model based on the key predictors. The end point was all‐cause mortality. The patients were classified into 3 risk categories at baseline (low, <2%; intermediate, ≥2% to 10%; high, ≥10%). External validation was performed by applying the score to an independent population with Chagas disease. After 2 years of follow‐up, 110 patients died, with an overall mortality rate of 3.505 deaths per 100 person‐years. Based on the nomogram, the independent predictors of mortality were assigned points: age (10 points per decade), New York Heart Association functional class higher than I (15 points), heart rate ≥80 beats/min (20 points), QRS duration ≥150 ms (15 points), and abnormal NT‐pro BNP adjusted by age (55 points). The observed mortality rates in the low‐, intermediate‐, and high‐risk groups were 0%, 3.6%, and 32.7%, respectively, in the derivation cohort and 3.2%, 8.7%, and 19.1%, respectively, in the validation cohort. The discrimination of the score was good in the development cohort (C statistic: 0.82), and validation cohort (C statistic: 0.71).

          Conclusions

          In a large population of patients with Chagas cardiomyopathy, a combination of risk factors accurately predicted early mortality. This helpful simple score could be used in remote areas with limited technological resources.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Development and validation of a risk score for predicting death in Chagas' heart disease.

          Chagas' disease is an important health problem in Latin America, and cardiac involvement is associated with substantial morbidity and mortality. We developed a model to predict the risk of death in patients with Chagas' heart disease. We retrospectively evaluated 424 outpatients from a regional Brazilian cohort. The association of potential risk factors with death was tested by Cox proportional-hazards analysis, and a risk score was created. The model was validated in 153 patients from a separate community hospital. During a mean follow-up of 7.9 years, 130 patients in the development cohort died. Six independent prognostic factors were identified, and each was assigned a number of points proportional to its regression coefficient: New York Heart Association class III or IV (5 points), evidence of cardiomegaly on radiography (5 points), left ventricular systolic dysfunction on echocardiography (3 points), nonsustained ventricular tachycardia on 24-hour Holter monitoring (3 points), low QRS voltage on electrocardiography (2 points), and male sex (2 points). We calculated risk scores for each patient and defined three risk groups: low risk (0 to 6 points), intermediate risk (7 to 11 points), and high risk (12 to 20 points). In the development cohort, the 10-year mortality rates for these three groups were 10 percent, 44 percent, and 84 percent, respectively. In the validation cohort, the corresponding mortality rates were 9 percent, 37 percent, and 85 percent. The C statistic for the point system was 0.84 in the development cohort and 0.81 in the validation cohort. A simple risk score was developed to predict death in Chagas' heart disease and was validated in an independent cohort. Copyright 2006 Massachusetts Medical Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            State of the art: using natriuretic peptide levels in clinical practice.

            Natriuretic peptide (NP) levels (B-type natriuretic peptide (BNP) and N-terminal proBNP) are now widely used in clinical practice and cardiovascular research throughout the world and have been incorporated into most national and international cardiovascular guidelines for heart failure. The role of NP levels in state-of-the-art clinical practice is evolving rapidly. This paper reviews and highlights ten key messages to clinicians: 1) NP levels are quantitative plasma biomarkers of heart failure (HF). 2) NP levels are accurate in the diagnosis of HF. 3) NP levels may help risk stratify emergency department (ED) patients with regard to the need for hospital admission or direct ED discharge. 4) NP levels help improve patient management and reduce total treatment costs in patients with acute dyspnoea. 5) NP levels at the time of admission are powerful predictors of outcome in predicting death and re-hospitalisation in HF patients. 6) NP levels at discharge aid in risk stratification of the HF patient. 7) NP-guided therapy may improve morbidity and/or mortality in chronic HF. 8) The combination of NP levels together with symptoms, signs and weight gain assists in the assessment of clinical decompensation in HF. 9) NP levels can accelerate accurate diagnosis of heart failure presenting in primary care. 10) NP levels may be helpful to screen for asymptomatic left ventricular dysfunction in high-risk patients.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association

              Chagas disease, resulting from the protozoan Trypanosoma cruzi, is an important cause of heart failure, stroke, arrhythmia, and sudden death. Traditionally regarded as a tropical disease found only in Central America and South America, Chagas disease now affects at least 300 000 residents of the United States and is growing in prevalence in other traditionally nonendemic areas. Healthcare providers and health systems outside of Latin America need to be equipped to recognize, diagnose, and treat Chagas disease and to prevent further disease transmission.
                Bookmark

                Author and article information

                Contributors
                tom@hc.ufmg.br
                Journal
                J Am Heart Assoc
                J Am Heart Assoc
                10.1002/(ISSN)2047-9980
                JAH3
                ahaoa
                Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
                John Wiley and Sons Inc. (Hoboken )
                2047-9980
                11 March 2020
                17 March 2020
                : 9
                : 6 ( doiID: 10.1002/jah3.v9.6 )
                : e014176
                Affiliations
                [ 1 ] Federal University of São João del‐Rei Divinópolis Brazil
                [ 2 ] Hospital das Clínicas and Faculdade de Medicina Universidade Federal de Minas Gerais Belo Horizonte Brazil
                [ 3 ] Department of Statistics Instituto de Ciência Exatas Universidade Federal de Minas Gerais Belo Horizonte Brazil
                [ 4 ] Health Science Program Universidade Estadual de Montes Claros Montes Claros Brazil
                [ 5 ] Laboratório de Investigação Médica (LIM03) Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil
                [ 6 ] Research and Education Institute – Hospital Sírio‐Libanês São Paulo Brazil
                [ 7 ] Instituto de Pesquisas René Rachou Fundação Oswaldo Cruz Belo Horizonte Brazil
                [ 8 ] Instituto de Medicina Tropical e Departamento de Moléstias Infecciosas e Parasitarias da Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil
                Author notes
                [*] [* ] Correspondence to: Antonio Luiz P. Ribeiro, MD, PhD, Centro de Telessaúde do Hospital das Clínicas, Universidade Federal de Minas Gerais, Av. Professor Alfredo Balena, 110, Santa Efigênia, 30130 100 – Belo Horizonte, Minas Gerais, Brazil. E‐mail: tom@ 123456hc.ufmg.br
                Article
                JAH34855
                10.1161/JAHA.119.014176
                7335521
                32157953
                5751e7f9-4c57-4579-819d-f78d8f562979
                © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 07 August 2019
                : 20 December 2019
                Page count
                Figures: 6, Tables: 4, Pages: 13, Words: 8323
                Funding
                Funded by: National Institutes of Health , open-funder-registry 10.13039/100000002;
                Award ID: P50 AI098461‐02
                Award ID: U19AI098461‐06
                Funded by: Brazilian National Research Council, CNPq
                Award ID: 467043/2014‐0
                Award ID: 310679/2016‐8
                Funded by: Minas Gerais State Research Agency, FAPEMIG
                Award ID: REDE 018‐14
                Award ID: PPM 00428‐17
                Funded by: Institute of Tropical Medicine/University of São Paulo
                Categories
                Original Research
                Original Research
                Heart Failure
                Custom metadata
                2.0
                17 March 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.8 mode:remove_FC converted:17.03.2020

                Cardiovascular Medicine
                chagas cardiomyopathy,chagas disease,mortality,risk prediction,risk score,cardiomyopathy,inflammatory heart disease

                Comments

                Comment on this article